Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 3

Conditions: Anogenital Human Papilloma Virus Infection; Condyloma Acuminata

Treatments: Biological: V501; Biological: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01862874

2015-002931-16 (EudraCT Number)

132237 (Registry Identifier)

V501-122 (Other Identifier)

Details and patient eligibility

About

A study to evaluate the efficacy and tolerability of V501 (quadrivalent Human Papilloma Virus [HPV] [Type 6, 11, 16 and 18] L1 Virus-Like Particle vaccine, GARDASIL™) in healthy, 16- to 26-year old Japanese males. The hypotheses tested are: 1) V501 reduces the combined incidence of HPV 6-, 11-, 16-, or 18-related persistent infection compared with placebo, and 2) V501 reduces the combined incidence of HPV 6-, 11-, 16-, or 18-related persistent infection, condyloma acuminata, penile/perianal/perineal intraepithelial neoplasia, or penile, perianal, or perineal cancer compared with placebo.

Enrollment: 1,124 patients

Sex: Male

Ages: 16 to 26 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Japanese
• No clinical evidence of gross genital lesion suggesting sexually-transmitted disease and no clinically present external genital warts
• Other inclusion criteria will be discussed with the investigator during screening

Exclusion criteria

• History of known prior vaccination with an HPV vaccine or plans to receive one outside the study
• History of external genital warts
• History of severe allergic reaction that required medical intervention
• Received immune globulin or blood-derived products in the past 6 months or plan to receive any before Month 7 of the study
• History of splenectomy, is currently immunocompromised, or has been diagnosed with immunodeficiency, Human Immunodeficiency Virus (HIV), lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition
• Received immunosuppressive therapy in the past year, excluding inhaled, nasal, or topical corticosteroids and certain regimens of systemic corticosteroids
• Known thrombocytopenia or coagulation disorder that would contraindicate intramuscular injections
• Ongoing alcohol or drug abuse within the past 12 months

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

1,124 participants in 2 patient groups, including a placebo group

V501

Experimental group

Description:

Participants received V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.

Treatment:

Biological: V501

Placebo

Placebo Comparator group

Description:

Participants received placebo 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.

Treatment:

Biological: Placebo